Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Exclusion Criteria23

• Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan;
• History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, thrombocytopenic diseases, etc;
• Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;
• Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications;
• Pregnancy, breastfeeding;
• An episode or exacerbation of congestive heart failure from any cause in the past 6 months;
• History of heart valve disease complicated by congestive heart failure within the past 6 months;
• Cardiac surgery with thoracotomy (eg. coronary artery bypass grafting or valve replacement surgery) within the past 6 months;
• Acute myocardial infarction in the past 6 months;
• Signs or symptoms of acute myocardial infarction upon admission, including electrocardiographic findings;
• Elevated serum troponin concentration upon admission (>0.1 μg/L) ;
• Acute arrhythmia (including any tachycardia or bradycardia) with hemodynamic instability (systolic blood pressure <100 mm Hg) upon admission;
• Acute or chronic lung diseases requiring long-term or intermittent oxygen therapy;
• Findings on physical examination of any of the following abnormalities: (1) Jugular venous distension (jugular venous pulsation >4 cm above the sternal angle); (2) Resting tachycardia due to congestive heart failure (heart rate > 100 per/min); (3) Third heart sound; (4) Abnormal hepatic jugular venous reflux; (5) Pitting edema of the lower extremities attributable to congestive heart failure or without apparent cause; (6) Rales in both lungs; (7) Or evidence of pulmonary edema, pleural effusion, or pulmonary vascular redistribution on chest X-ray;
• Severe chronic anemia (hemoglobin < 75 g/L);
• Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) < 60 mL/min;
• Refractory hypertension that is difficult to control by medication (defined as systolic blood pressure > 220 mmHg, or diastolic blood pressure > 110 mmHg);
• Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 1.5 times the upper limit of the normal value.
• History of albumin allergy or known allergy to albumin;
• Patients with severe mental disorders or dementia who are unable to cooperate in completing informed consent and follow-up content;
• The expected survival time is less than 90 days (such as comorbidity with malignant tumor or severe systemic diseases etc.);
• Patients who have participated in other interventional clinical studies within 30 days before randomization or are currently participating in other interventional clinical studies.
• The investigator believes that the subject has other conditions making it unsuitable for participating in this study.